In fiscal 2025, which ended Dec 31, 2025, TuHURA BIOSCIENCES, INC./NV reported revenue of $0. It recorded a net loss of $30.1 million. Diluted earnings per share were -$0.63. Over the twelve months ended Mar 31, 2026, revenue was $0 and the net loss was $30.9 million.
USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.
| Line |
FY 2026
Mar 31, 2026
|
FY 2025
Dec 31, 2025
|
FY 2024
Dec 31, 2024
|
FY 2024
Jun 30, 2024
|
FY 2023
Jun 30, 2023
|
FY 2022
Jun 30, 2022
|
FY 2021
Jun 30, 2021
|
FY 2020
Jun 30, 2020
|
FY 2019
Jun 30, 2019
|
FY 2018
Jun 30, 2018
|
FY 2017
Jun 30, 2017
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
0
|
0
|
0
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Research and development |
21
+31.9%
|
21
+671.0%
|
13
+43.2%
|
3
-71.4%
|
9
-38.6%
|
15
+28.4%
|
12
+225.5%
|
4
-0.9%
|
4
+151.3%
|
-7
-42.6%
|
-5
-248.9%
|
| Selling, general and administrative |
8
+64.3%
|
8
+31.0%
|
4
-29.4%
|
6
+5.5%
|
5
-27.0%
|
8
-23.0%
|
10
+116.1%
|
5
-4.7%
|
5
+217.2%
|
-4
-21.8%
|
-3
-216.3%
|
| Pretax income |
—
|
-30
-38.6%
|
-22
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Income tax |
—
|
0
-57.5%
|
0
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Net income |
-31
-21.8%
|
-30
-261.2%
|
-22
-48.0%
|
-8
+43.2%
|
-15
+35.4%
|
-23
+40.8%
|
-38
-319.7%
|
-9
-13.4%
|
-8
-172.3%
|
11
+37.8%
|
8
-8.8%
|
| Basic EPS |
-0.60
+33.2%
|
-0.63
-96.9%
|
-1.21
+86.9%
|
-0.32
+96.5%
|
-9.27
+64.1%
|
-25.80
-1512.5%
|
-1.60
-83.9%
|
-0.87
-127.5%
|
3.16
-41.7%
|
5.42
+632.4%
|
0.74
-10.8%
|
| Diluted EPS |
-0.60
|
-0.63
+47.9%
|
-1.21
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Weighted average shares, basic |
52
+76.9%
|
48
+81.9%
|
19
+1052.0%
|
26
+1526.7%
|
2
+66.3%
|
1
-96.2%
|
26
+147.9%
|
10
+305.6%
|
3
+23.4%
|
2
-82.7%
|
12
+10.0%
|
| Weighted average shares, diluted |
52
|
48
+156.8%
|
19
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Other measures | |||||||||||
| Depreciation and amortization |
0
|
0
-38.9%
|
0
+94.5%
|
0
+94.5%
|
0
+0.0%
|
0
+100.0%
|
0
|
—
|
—
|
—
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.
New to this? Read How to Read an Income Statement, With a Real Example.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- HURA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Tampa, FL
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1498382
- Former names
- Kintara Therapeutics, Inc. (until Oct 22, 2024); DelMar Pharmaceuticals, Inc. (until Aug 18, 2020); Berry Only Inc. (until Jan 18, 2013)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.